Table 1 Baseline characteristics in group of patients in the COVID-19 registry with MDS record linkage (N = 18,772)
|  | 1.Wave 1 01/02/2020- 24/05/2020 | 2.In-between 25/05/2020–04/10/2020 | 3.Wave 2.1 05/10/2020- 31/01/2021 | 4.Wave 2.2 01/02/2021- 24/05/2021 | 5.In-between 25/05/2021- 04/10/2021 | 6.Wave 3.1 05/10/2021- 31/01/2022 | 7.Wave 3.2 01/02/2022- 24/05/2022 | 8.In-between 25/05/2022- 04/10/2022 | 9.Endemic 05/10/2022- 31/01/2023 |
|---|---|---|---|---|---|---|---|---|---|
Number (N) of patients | 2816 | 507 | 4470 | 4663 | 1292 | 3234 | 1239 | 606 | 690 |
with MDS linkage: N (%) | 2740 (97.3) | 490 (96.6) | 4300 (96.2) | 4602 (98.7) | 1272 (98.5) | 3074 (95.1) | 1141 (92.1) | 555 (91.6) | 598 (86.7) |
Mean age (years) (SD) | 63.2 (11.3) | 61.9 (12.8) | 64.3 (11.3) | 61.5 (11.7) | 55.7 (14.4) | 60.4 (13.2) | 62.6 (14.7) | 63.3 (15.9) | 66.4 (13.8) |
Gender: Male N (%) | 1976 (72.1) | 334 (68.2) | 3068 (71.3) | 3082 (67.0) | 777 (61.1) | 2049 (66.7) | 688 (60.3) | 338 (60.9) | 389 (65.1) |
Comorbidity N (%): | |||||||||
 Immune insufficiency | 208 (7.6) | 40 (8.2) | 459 (10.7) | 416 (9.0) | 133 (10.5) | 325 (10.6) | 254 (22.3) | 125 (22.5) | 119 (19.9) |
 Renal insufficiency | 73 (2.7) | 19 (3.9) | 252 (5.9) | 153 (3.3) | 44 (3.5) | 137 (4.5) | 99 (8.7) | 48 (8.6) | 66 (11) |
 Respiratory insufficiency | 306 (11.2) | 50 (10.2) | 633 (14.7) | 561 (12.2) | 129 (10.1) | 331 (10.8) | 209 (18.3) | 106 (19.1) | 147 (24.6) |
 Cardiovascular | 34 (1.2) | 7 (1.4) | 84 (2.0) | 68 (1.5) | 20 (1.6) | 37 (1.2) | 42 (3.7) | 21 (3.8) | 26 (4.3) |
 Malignancy | 66 (2.4) | 13 (2.7) | 144 (3.3) | 88 (1.9) | 31 (2.4) | 80 (2.6) | 104 (9.1) | 56 (10.1) | 55 (9.2) |
 Liver cirrhosis | 3 (0.1) | 2 (0.4) | 22 (0.5) | 23 (0.5) | 8 (0.6) | 20 (0.7) | 13 (1.1) | 8 (1.4) | 7 (1.2) |
 Diabetes mellitus | 522 (19.1) | 146 (29.8) | 1116 (26) | 972 (21.1) | 268 (21.1) | 631 (20.5) | 235 (20.6) | 104 (18.7) | 129 (21.6) |
 At least 1 of these N (%) | 977 (35.7) | 218 (44.5) | 1998 (46.5) | 1801 (39.1) | 480 (37.8) | 1155 (37.6) | 618 (54.1) | 297 (53.5) | 352 (58.9) |
 Mean BMI (kg/m2) (SD) | 28.7 (4.99) | 29.39 (5.59) | 29.42 (5.38) | 30.05 (5.81) | 30.31 (6.42) | 29.36 (5.78) | 27.66 (6.26) | 26.4 (5.55) | 27.12 (6.28) |
 BMI > 30 N (%) | 843 (30.8) | 180 (36.7) | 1651 (38.4) | 1974 (42.9) | 558 (43.9) | 1222 (39.8) | 307 (26.9) | 105 (18.9) | 135 (22.6) |
APACHE-IV 1st diagnosis: | Â | ||||||||
 Viral pneumonia/ ARDS/ | 2550 (93.0) | 424 (86.5) | 3940 (91.7) | 4337 (94.2) | 1179 (92.7) | 2710 (88.2) | 589 (51.7) | 207 (37.3) | 251 (41.9) |
Sars-Cov-2 N (%) | |||||||||
 Mean APACHE-III (SD) | 60.21 (21.54) | 60.14 (23.37) | 63.74 (21.36) | 60.09 (19.82) | 58.16 (20.45) | 61.52 (22.75) | 66.27 (27.09) | 70.82 (30.55) | 69.98 (28.47) |
 1.ARDS (APACHE-IV) N(%) | 436 (15.9) | 56 (11.4) | 445 (10.3) | 617 (13.4) | 159 (12.5) | 425 (13.8) | 58 (5.1) | 8 (1.4) | 15 (2.5) |
 2.PaO2/FiO2 ratio < 300 | 2379 (86.8) | 394 (80.4) | 3795 (88.3) | 4202 (91.3) | 1141 (89.7) | 2697 (87.7) | 787 (69.0) | 351 (63.2) | 386 (64.5) |
 1. and/ or 2. N (%) | 2439 (89.0) | 403 (82.2) | 3809 (88.6) | 4224 (91.8) | 1146 (90.1) | 2707 (88.1) | 788 (69.1) | 352 (63.4) | 387 (64.7) |